Conflicting results were reported by small clinical trials; only modest hypoglycemic effects less distinct than for metformin were shown in type 2 diabetes mellitus patients [47], and no effect on the levels of plasma insulin and glucose was detectable in obese men [48], revealing the inconsistent outcomes for Momordica charantia regarding clinical trials [49]. This evidence concerns the gene INS and diabetes mellitus.